BRAIN Biotech (BNN.DE) Stock Price

BRAIN Biotech Price

XETRA·CLOSED
2.65EUR-0.18 (-6.57 %)
Market closed

Over the last 13 years BRAIN Biotech grew revenue by 15.7% annually, reaching 49.62 M EUR. For BRAIN Biotech, the net margin of -23.7% is down versus -13.0% a few years ago. The consensus 12-month price target for BRAIN Biotech is 5.10 EUR, about 92.5% above where the stock trades today. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 27% above its 52-week low.

BRAIN Biotech stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of BRAIN Biotech over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how BRAIN Biotech stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing BRAIN Biotech's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

BRAIN Biotech Stock Price History
DateBRAIN Biotech Price
8/21/20262.65 EUR
8/20/20262.83 EUR
8/19/20262.89 EUR
8/18/20262.87 EUR
8/17/20262.88 EUR
8/14/20262.83 EUR
8/13/20262.80 EUR
8/12/20262.80 EUR
8/11/20262.81 EUR
8/10/20262.83 EUR
8/7/20262.78 EUR
8/6/20262.83 EUR
8/5/20262.89 EUR
8/4/20262.78 EUR
7/31/20262.91 EUR
7/30/20262.81 EUR
7/29/20262.75 EUR
7/28/20262.72 EUR
7/27/20262.78 EUR
7/24/20262.78 EUR
7/23/20262.82 EUR
7/22/20262.82 EUR
7/21/20262.89 EUR
7/20/20262.85 EUR
7/17/20262.71 EUR
7/16/20262.78 EUR
7/15/20262.79 EUR
7/14/20262.92 EUR
7/13/20262.91 EUR
7/10/20262.82 EUR
7/9/20262.91 EUR
7/8/20262.76 EUR
7/7/20262.86 EUR
7/6/20262.71 EUR
7/3/20262.93 EUR
7/2/20262.90 EUR
7/1/20262.86 EUR
6/30/20262.95 EUR
6/29/20262.80 EUR
6/26/20262.78 EUR
6/25/20262.82 EUR
6/24/20262.83 EUR
6/23/20262.83 EUR
6/22/20262.84 EUR
6/19/20262.90 EUR
6/18/20262.90 EUR
6/17/20262.95 EUR
6/16/20262.86 EUR
6/15/20262.84 EUR
6/12/20262.89 EUR
6/11/20262.71 EUR
6/10/20262.73 EUR
6/9/20262.75 EUR
6/8/20262.87 EUR
6/5/20262.87 EUR
6/4/20262.93 EUR
6/3/20262.98 EUR
6/2/20263.00 EUR
6/1/20263.01 EUR
5/29/20262.93 EUR
5/28/20262.97 EUR
5/27/20262.91 EUR
5/26/20262.91 EUR
5/25/20263.02 EUR
5/22/20262.96 EUR
5/21/20263.24 EUR
5/20/20263.01 EUR
5/19/20263.02 EUR
5/18/20263.07 EUR
5/15/20263.24 EUR
5/14/20263.25 EUR
5/13/20263.30 EUR
5/12/20263.34 EUR
5/11/20263.31 EUR
5/8/20263.17 EUR
5/7/20263.25 EUR
5/6/20263.17 EUR
5/5/20262.94 EUR
5/4/20262.91 EUR
4/30/20262.76 EUR
4/29/20262.76 EUR
4/28/20262.67 EUR
4/27/20262.51 EUR
4/24/20262.51 EUR
4/23/20262.47 EUR
4/22/20262.56 EUR
4/21/20262.49 EUR
4/20/20262.54 EUR
4/17/20262.50 EUR
4/16/20262.47 EUR
4/15/20262.29 EUR
4/14/20262.41 EUR
4/13/20262.39 EUR
4/10/20262.40 EUR
4/9/20262.40 EUR
4/8/20262.40 EUR
4/7/20262.69 EUR
4/2/20262.52 EUR
3/27/20262.37 EUR
3/26/20262.63 EUR
3/25/20262.48 EUR
3/24/20262.48 EUR
3/23/20262.40 EUR
3/20/20262.33 EUR
3/19/20262.45 EUR
3/18/20262.54 EUR
3/17/20262.51 EUR
3/16/20262.57 EUR
3/13/20262.70 EUR
3/12/20262.69 EUR
3/11/20262.56 EUR
3/10/20262.56 EUR
3/9/20262.29 EUR
3/6/20262.34 EUR
3/5/20262.36 EUR
3/4/20262.36 EUR
3/3/20262.42 EUR
3/2/20262.44 EUR
2/27/20262.54 EUR
2/26/20262.53 EUR
2/25/20262.81 EUR
2/24/20262.16 EUR
2/23/20262.18 EUR
2/20/20262.18 EUR
2/19/20262.25 EUR
2/18/20262.25 EUR
2/17/20262.24 EUR
2/16/20262.23 EUR
2/13/20262.26 EUR
2/12/20262.23 EUR
2/11/20262.21 EUR
2/10/20262.28 EUR
2/9/20262.18 EUR
2/6/20262.24 EUR
2/5/20262.18 EUR
2/4/20262.24 EUR
2/3/20262.24 EUR
2/2/20262.20 EUR
1/30/20262.32 EUR
1/29/20262.29 EUR
1/28/20262.34 EUR
1/27/20262.35 EUR
1/26/20262.28 EUR
1/23/20262.34 EUR
1/22/20262.36 EUR
1/21/20262.36 EUR
1/20/20262.48 EUR
1/19/20262.42 EUR
1/16/20262.42 EUR
1/15/20262.46 EUR
1/14/20262.44 EUR
1/13/20262.70 EUR
1/12/20262.68 EUR
1/9/20262.75 EUR
1/8/20262.71 EUR
1/7/20262.71 EUR
1/6/20262.70 EUR
1/5/20262.60 EUR
1/2/20262.59 EUR
12/30/20252.52 EUR
12/29/20252.47 EUR
12/23/20252.60 EUR
12/22/20252.58 EUR
12/19/20252.63 EUR
12/18/20252.64 EUR
12/17/20252.72 EUR
12/16/20252.88 EUR
12/15/20252.94 EUR
12/12/20252.97 EUR
12/11/20253.04 EUR
12/10/20252.90 EUR
12/9/20253.06 EUR
12/8/20253.02 EUR
12/5/20253.03 EUR
12/4/20253.05 EUR
12/3/20253.13 EUR
12/2/20253.06 EUR
12/1/20252.97 EUR
11/28/20253.12 EUR
11/27/20253.12 EUR
11/26/20252.96 EUR
11/25/20252.74 EUR
11/24/20253.07 EUR
11/21/20253.66 EUR
11/20/20253.30 EUR
11/19/20253.05 EUR
11/18/20252.89 EUR
11/17/20252.82 EUR
11/14/20252.46 EUR
11/13/20252.43 EUR
11/12/20252.41 EUR
11/11/20252.37 EUR
11/10/20252.38 EUR
11/7/20252.38 EUR
11/6/20252.39 EUR
11/5/20252.28 EUR
11/4/20252.28 EUR
11/3/20252.33 EUR
10/31/20252.19 EUR
10/30/20252.17 EUR
10/29/20252.14 EUR
10/28/20252.17 EUR
10/27/20252.25 EUR
10/24/20252.27 EUR
10/23/20252.22 EUR
10/22/20252.26 EUR
10/21/20252.32 EUR
10/20/20252.32 EUR
10/17/20252.16 EUR
10/16/20252.11 EUR
10/15/20252.11 EUR
10/14/20252.14 EUR
10/13/20252.09 EUR
10/10/20252.11 EUR
10/9/20252.13 EUR
10/8/20252.09 EUR
10/7/20252.13 EUR
10/6/20252.25 EUR
10/3/20252.20 EUR
10/2/20252.28 EUR
10/1/20252.16 EUR
9/30/20252.18 EUR
9/29/20252.22 EUR
9/26/20252.25 EUR
9/25/20252.15 EUR
9/24/20252.18 EUR
9/23/20252.26 EUR
9/22/20252.20 EUR
9/19/20252.19 EUR
9/18/20252.17 EUR
9/17/20252.18 EUR
9/16/20252.21 EUR
9/15/20252.26 EUR
9/12/20252.24 EUR
9/11/20252.27 EUR
9/10/20252.22 EUR
9/9/20252.22 EUR
9/8/20252.27 EUR
9/5/20252.30 EUR
9/4/20252.19 EUR
9/3/20252.22 EUR
9/2/20252.29 EUR
9/1/20252.30 EUR
8/29/20252.24 EUR
8/28/20252.30 EUR
8/27/20252.20 EUR
8/26/20252.11 EUR
8/25/20252.20 EUR
Access this data via the Eulerpool API
Get Free API Key

BRAIN Biotech Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
55.34 M EUR
-6.63 M EUR
-8.28 M EUR
Jan 1, 2024
54.63 M EUR
-8.85 M EUR
-11.13 M EUR
Jan 1, 2025
49.62 M EUR
-8.51 M EUR
-11.74 M EUR
Jan 1, 2026 (e)
52.53 M EUR
-6.71 M EUR
-7.10 M EUR
Jan 1, 2027 (e)
58.72 M EUR
-7.50 M EUR
-1.08 M EUR
Jan 1, 2028 (e)
64.81 M EUR
-8.28 M EUR
7.90 M EUR
Jan 1, 2029 (e)
66.67 M EUR
-8.52 M EUR
-3.06 M EUR
Jan 1, 2030 (e)
74.91 M EUR
-9.57 M EUR
2.88 M EUR

BRAIN Biotech Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 23, 2026, 3:10 PM
 
REVENUEM EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
21.0022.0024.0027.0038.0038.0038.0049.0055.0054.0049.0052.0058.0064.0066.0074.00
75.004.769.0912.5040.74––28.9512.24-1.82-9.266.1211.5410.343.1312.12
47.6250.0050.0048.1555.2655.26-2.632.045.453.704.084.084.084.084.084.08
10.0011.0012.0013.0021.0021.00-1.001.003.002.002.002.122.372.612.693.02
-4.00-13.00-9.00-10.00-5.00-8.00-6.00-7.00-6.00-8.00-8.00-6.00-7.00-8.00-8.00-9.00
-19.05-59.09-37.50-37.04-13.16-21.05-15.79-14.29-10.91-14.81-16.33-11.54-12.07-12.50-12.12-12.16
-5.00-14.00-9.00-8.00-10.00-9.00-4.00-6.00-8.00-11.00-11.00-7.00-1.007.00-3.002.00
–180.00-35.71-11.1125.00-10.00-55.5650.0033.3337.50–-36.36-85.71-800.00-142.86-166.67
12.8616.4118.0618.0618.0619.8621.8521.8521.8521.8521.8521.8521.8521.8521.8521.85
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales BRAIN Biotech generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue BRAIN Biotech retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare BRAIN Biotech's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares BRAIN Biotech has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against BRAIN Biotech's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

BRAIN Biotech stock margins

The BRAIN Biotech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BRAIN Biotech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BRAIN Biotech.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
-5.09 %
-17.06 %
-12.95 %
Jan 1, 2022
2.88 %
-15.20 %
-13.31 %
Jan 1, 2023
6.27 %
-11.98 %
-14.96 %
Jan 1, 2024
0.73 %
-16.20 %
-20.37 %
Jan 1, 2025
4.04 %
-17.15 %
-23.66 %
Jan 1, 2026 (e)
4.04 %
-12.77 %
-13.52 %
Jan 1, 2027 (e)
4.04 %
-12.77 %
-1.84 %
Jan 1, 2028 (e)
4.04 %
-12.77 %
12.19 %

BRAIN Biotech Stock Revenue, EBIT, Earnings per Share

The BRAIN Biotech earnings per share therefore indicates how much revenue BRAIN Biotech has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
1.76 EUR
-0.30 EUR
-0.23 EUR
Jan 1, 2022
2.27 EUR
-0.34 EUR
-0.30 EUR
Jan 1, 2023
2.53 EUR
-0.30 EUR
-0.38 EUR
Jan 1, 2024
2.50 EUR
-0.41 EUR
-0.51 EUR
Jan 1, 2025
2.27 EUR
-0.39 EUR
-0.54 EUR
Jan 1, 2026 (e)
2.40 EUR
-0.31 EUR
-0.33 EUR
Jan 1, 2027 (e)
2.69 EUR
-0.34 EUR
-0.05 EUR
Jan 1, 2028 (e)
2.97 EUR
-0.38 EUR
0.36 EUR

BRAIN Biotech business model & stock analysis

The company BRAIN Biotechnology Research and Information Network AG is a German company specializing in biotechnology. The company was founded in 1993 and is headquartered in Zwingenberg, Germany. BRAIN has been listed on the Frankfurt Stock Exchange since 2006 and has over 500 employees worldwide. The history of BRAIN dates back to the 1980s when the Senckenberg Institute for Biodiversity and Climate Research in Frankfurt developed a new method for isolating microorganisms. These are called extremophilic bacteria and fungi, which live in extreme environments such as hot springs or salty soils and produce special enzymes. These enzymes can be used in various applications, such as the food industry or the development of new drugs. BRAIN has further developed this method and built an extensive portfolio of enzymes, microorganisms, and natural substances. The company is divided into three areas: 1. BioIndustrial: Enzymes and microorganisms for industrial applications are developed here, such as for the production of detergents, paper, or bioethanol. 2. BioScience: This area focuses on the research of natural substances and active ingredients from microorganisms for the pharmaceutical and cosmetics industries. 3. Consumer Products: BRAIN develops products for end consumers here, such as probiotics or enzyme preparations for digestion promotion. BRAIN works closely with leading companies to develop innovative solutions for their needs. The company is not only focused on the development of new products but also on the optimization of existing processes. BRAIN relies on sustainable and environmentally friendly production. An example of a product developed by BRAIN is an enzyme used in the production of fruit juice. This enzyme breaks down pectin, which is found in many types of fruit and causes the juice to become cloudy. By using this enzyme, the juice can be made clearer and more durable without the need for artificial additives. BRAIN also uses a special enzyme in the production of soy milk to improve taste and consistency. Overall, BRAIN has filed over 600 patents and works with more than 170 customers in various industries. The company is committed to preserving biodiversity and promoting sustainability in production. In summary, BRAIN Biotechnology Research and Information Network AG is a company specializing in the research and development of enzymes, microorganisms, and natural substances. The company has a long history and can look back on successful collaborations with leading companies in various industries. BRAIN focuses on sustainability and environmental compatibility in production and has a broad portfolio of products that can be used in various applications.

BRAIN Biotech SWOT Analysis

Strengths

BRAIN Biotechnology Research and Information Network AG has established itself as a leader in biotechnology research and development. The company possesses a highly skilled team of researchers and scientists who are dedicated to innovation and problem-solving in the biotech industry.

BRAIN AG offers a wide range of biotechnological products across various industries, including food and beverages, healthcare, and agriculture. This diversity in its product portfolio enables the company to cater to different market demands and mitigate risks associated with depending on a single product.

The company has strategic partnerships with leading organizations in the biotechnology and pharmaceutical sectors. These partnerships provide access to additional resources, expertise, and market opportunities, enhancing BRAIN AG's competitive advantage and market positioning.

Weaknesses

BRAIN AG heavily relies on collaborations with external partners for the commercialization and distribution of its products. This dependence on external factors may introduce uncertainties and challenges in terms of maintaining control over the supply chain, pricing, and market presence.

The success of BRAIN AG is closely tied to market conditions and customer demand for biotechnological solutions. Economic downturns or shifts in consumer preferences could impact the company's revenue and profitability, making it vulnerable to market fluctuations.

Opportunities

The biotechnology industry continues to witness significant growth due to advancements in technology, increasing need for sustainable solutions, and rising healthcare demands. BRAIN AG can capitalize on this opportunity by further developing its products and expanding its market presence.

The company can explore untapped markets within the biotechnology sector, such as pharmaceuticals, renewable energy, and environmental solutions. By diversifying its offerings and targeting new customer segments, BRAIN AG can broaden its market reach and drive long-term growth.

Threats

BRAIN AG operates in a highly competitive industry, facing competition from both established players and emerging startups. To maintain its market position, the company must continually innovate, differentiate its offerings, and adapt to changing customer needs to stay ahead of the competition.

The biotechnology sector is subject to stringent regulations and compliance requirements, which may pose challenges for BRAIN AG in terms of product development, safety testing, and commercialization. Adhering to these regulations and staying up-to-date with changing policies is crucial to avoid potential legal and reputational risks.

BRAIN Biotech Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

BRAIN Biotech historical P/E ratio, EBIT multiple, and P/S ratio

BRAIN Biotech annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

BRAIN Biotech shares outstanding

The number of shares of BRAIN Biotech was 21.85 M in 2025. This indicates how many shares BRAIN Biotech is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
21.85 M Stocks
Jan 1, 2022
21.85 M Stocks
Jan 1, 2023
21.85 M Stocks
Jan 1, 2024
21.85 M Stocks
Jan 1, 2025
21.85 M Stocks
Jan 1, 2026 (e)
21.85 M Stocks
Jan 1, 2027 (e)
21.85 M Stocks
Jan 1, 2028 (e)
21.85 M Stocks

Current BRAIN Biotech forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
13.79 %
Buy
88.89 % (8)
Hold
11.11 % (1)
Sell
0.00 % (0)
12M Price Target
5.10
Last Price
2.65
Currency
EUR
12M Return Potential
92.45 %
LTM Return
0 %

BRAIN Biotech Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/31/2020-EUR-10.15 MEUR-2020 Q3
2/28/2020-EUR-10.15 MEUR-2020 Q1
1/14/2020-EUR-11.16 MEUR-2019 Q4
1/16/2017-0.10EUR-5.99 MEUR-2016 Q4

BRAIN Biotech shareholder structure

% Name
45.39999%
Putsch (Martin)
Putsch (Martin)
7.50000%
Founders and management of BRAIN Biotechnology Research and Information
Founders and management of BRAIN Biotechnology Research and Information
5.60000%
Hopp (Daniel)
Hopp (Daniel)
4.98795%
Universal-Investment-Gesellschaft mbH
Universal-Investment-Gesellschaft mbH
1.91999%
Deka Investment GmbH
Deka Investment GmbH
1.50766%
MEAG Munich ERGO Kapitalanlagegesellschaft mbH
MEAG Munich ERGO Kapitalanlagegesellschaft mbH

BRAIN Biotech Beneficial Ownership Filings (SEC 13D/G)

Free Float
47.8%
Float Shares
-
Shares Outstanding
-

BRAIN Biotech Executives and Management Board

8 members · avg. age 58 · 38 % women

AM

Mr. Adriaan Moelker (61)

Chairman of the Management Board, Chief Executive Officer

620,000.00 EUR

Management

MS

Mr. Michael Schneider (55)

Chief Financial Officer, Member of the Management Board

–
MS

Ms. Martina Schuster

Investor Relations · since 2021

–

Board of Directors

AE

Dr. Anna Eichhorn (53)

Independent Deputy Chairman of the Supervisory Board · since 2017

53,000.00 EUR
MM

Dr. Michael Majerus (64)

Independent Chairman of the Supervisory Board · since 2019

51,000.00 EUR
SC

Mr. Stephen Catling (60)

Independent Member of the Supervisory Board

31,000.00 EUR
FS

Dr. Florian Schnabel (55)

Member of the Supervisory Board

–
CU

Ms. Christine Uekert (61)

Member of the Supervisory Board

–

BRAIN Biotech Supply Chain

BRAIN Biotech Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
19 companies
#NameTrend
1
Evonik Industries
Supplier·Customer·Chemicals·DE
-0.04
-0.49
-0.19
0.68
0.68
0.73
2
Coty A
Supplier·Customer·Personal Products·US
-0.62
0.80
0.84
0.69
0.30
0.71
3
Celanese
Supplier·Customer·Chemicals·US
-0.56
-0.08
-0.53
0.49
0.43
0.69
4
BASF
Supplier·Customer·Chemicals·DE
-0.11
0.32
0.62
0.74
0.76
0.68
5
DuPont de Nemours
Supplier·Customer·Chemicals·US
-0.55
0.55
0.77
0.86
0.36
0.68
#NameTrend
1
Pharvaris
Supplier·Customer·Pharmaceuticals·NL
-0.30
0.38
0.50
0.04
0.06
—
2
RWE
Supplier·Customer·Independent Power and Renewable Electricity Producers·DE
0.06
-0.29
-0.60
-0.67
-0.80
-0.26
3
Bayer
Supplier·Customer·Pharmaceuticals·DE
-0.02
0.66
-0.63
-0.73
-0.70
-0.26
4
Suedzucker
Supplier·Customer·Food Products·DE
-0.44
0.42
-0.49
0.19
0.59
-0.21
5
General Mills
Supplier·Customer·Food Products·US
0.20
-0.23
-0.61
-0.35
-0.76
-0.15

Frequently asked questions about BRAIN Biotech

The business model of BRAIN Biotechnology Research and Information Network AG revolves around the development and commercialization of innovative solutions for the bio-based economy. BRAIN offers industrial partners access to a wide range of bioactive substances and enzymes derived from natural resources. The company utilizes its proprietary BioArchive and BioXtractor technologies to discover and optimize these valuable compounds. BRAIN then collaborates with various industries, including the chemical, pharmaceutical, and food sectors, to develop customized solutions for their specific needs. By leveraging its expertise in biotechnology and bioinformatics, BRAIN aims to contribute to sustainable and resource-efficient processes in industries worldwide.

BRAIN Biotechnology Research and Information Network AG is primarily active in the biotechnology industry.

The main competitors of BRAIN Biotechnology Research and Information Network AG in the market include companies such as BASF SE, Novozymes A/S, and Codexis, Inc. These companies are also involved in the biotechnology and research sectors, offering innovative solutions and products. However, BRAIN AG differentiates itself through its comprehensive portfolio of bio-based products, cutting-edge technologies, and expertise in biotechnology, strand synthesis, and enzyme engineering. This allows BRAIN AG to offer customized and sustainable solutions for various industries, including food and nutrition, pharmaceuticals, and cosmetics.

BRAIN Biotechnology Research and Information Network AG, commonly known as BRAIN AG, is a renowned company in the biotechnology sector. Established in 1993, BRAIN AG has a strong history of pioneering advancements in the field of industrial biotechnology. This German-based company specializes in the discovery and development of innovative bio-based products and solutions. With a focus on exploiting the vast potential of nature's biodiversity, BRAIN AG applies its unique BioArchive to identify novel enzymes, microorganisms, and natural substances for various industrial applications. Over the years, BRAIN AG has successfully collaborated with numerous industry partners, leading to groundbreaking innovations in areas such as agriculture, consumer goods, and pharmaceuticals. With its rich history and expertise, BRAIN AG continues to redefine the boundaries of biotechnological research and development.

BRAIN Biotechnology Research and Information Network AG has achieved several significant milestones since its inception. The company has successfully established itself as a leading provider of innovative solutions in the field of biotechnology research and information. BRAIN AG has developed groundbreaking technologies and solutions that have revolutionized many industries, including pharmaceuticals, agriculture, and nutrition. The company's collaborative efforts with renowned partners have resulted in numerous successful research projects and product developments. Additionally, BRAIN AG has received prestigious recognition and awards for its outstanding contributions to the biotechnology sector. Overall, BRAIN Biotechnology Research and Information Network AG continues to make remarkable strides in advancing the boundaries of biotechnology innovation and research.

BRAIN Biotechnology Research and Information Network AG primarily operates in Germany and has a strong presence in Europe.

BRAIN Biotechnology Research and Information Network AG represents core values of innovation, collaboration, and sustainable development in the biotechnology research and information sector. With a steadfast commitment to utilizing cutting-edge technology, BRAIN AG strives to revolutionize industries by harnessing the power of nature's vast biodiversity. By fostering strong partnerships and collaborations, BRAIN AG aims to provide novel solutions that address challenges in areas such as healthcare, nutrition, and consumer goods. With a focus on sustainability, BRAIN AG actively promotes environmentally friendly practices and the responsible use of resources. BRAIN AG's corporate philosophy revolves around unlocking the potential of nature and delivering value to its stakeholders through pioneering biotechnological research and information networks.

Analysts currently set an average price target of 5.34 EUR for the BRAIN Biotech stock (median: 5.10 EUR), implying +101.7 % versus the latest price. The consensus is based on 9 analyst ratings.

BRAIN Biotech Analyst Price Targets 2026

9 analysts currently rate the BRAIN Biotech stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect BRAIN Biotech to generate revenue of 52.53 M EUR and earnings per share of -0.33 EUR.

BRAIN Biotech Analyst Price Targets 2026

The BRAIN Biotech share (BNN.DE) is listed on 7 stock exchanges, including: XETRA (BNN.DE), Frankfurt (BNN.F), München (BNN.MU), Düsseldorf (BNN.DU), Hamburg (BNN.HM), London (0RFI.L), SIX (Zürich) (BNN.SW).

The BRAIN Biotechnology Research and Information Network AG specializes in the research and development of innovative biotechnological products. The company is divided into three different divisions: BioScience, BioIndustrial, and BioResources. The BioScience division focuses primarily on identifying and characterizing new active substances and enzymes from nature. BRAIN works closely with various global industrial companies to translate research findings into marketable products. The BioScience division is also responsible for conducting customized research projects tailored to the specific needs of the companies. BRAIN's BioIndustrial division focuses on the development and production of customized enzymes and microorganisms for industrial applications in various industries, such as food, paper, and textile. By using biotechnological processes, products can be produced in a more environmentally friendly manner and resources can be saved. BRAIN's BioResources division specializes in the use of biomass for the extraction of valuable raw materials. Sustainable and environmentally friendly methods are used to produce high-quality products such as bioenergy, biorefinery products, and biopolymers from biological waste and residues. BRAIN offers customers a comprehensive range of services in the field of biotechnological research and development. The company emphasizes a strong customer-oriented approach and close collaboration with industry partners. BRAIN has a large number of patents and market approvals that emphasize the high quality of its products. BRAIN's products include enzymes for the food industry for cheese and bread production, as well as specially adapted microorganisms for the production of bioethanol or biogas. In the cosmetics industry, BRAIN also offers innovative solutions such as natural active ingredients for skin and hair care products. In summary, BRAIN offers a wide range of biotechnological solutions for sustainable and efficient production in various industries. The close collaboration with industry partners allows for meeting individual customer needs and offering tailored solutions. BRAIN is an innovative company that is globally at the forefront of biotechnology due to its high level of research and development performance and the use of state-of-the-art technology. BRAIN specializes in the research and development of biotechnological products in various industries.

The expected revenue of BRAIN Biotech is 52.53 M EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of BRAIN Biotech is -7.10 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of BRAIN Biotech is currently -8.15. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the BRAIN Biotech stock.

The price-to-sales ratio (P/S) of BRAIN Biotech is currently 1.10. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the BRAIN Biotech stock.

The Eulerpool Quality Score for BRAIN Biotech is 3/10.

The ISIN of BRAIN Biotech is DE0005203947. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of BRAIN Biotech is 520394. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of BRAIN Biotech is BNN.DE. The ticker symbol is used to trade BRAIN Biotech shares on the stock exchange.

BRAIN Biotech paid dividends every year for the past 0 years.

BRAIN Biotech is assigned to the 'Commodities' sector.

The dividends of BRAIN Biotech are distributed in EUR.

All fundamentals and in-depth analysis of BRAIN Biotech

Our stock analysis for BRAIN Biotech stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BRAIN Biotech. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

BRAIN Biotech Stock
BRAIN Biotech Revenue→
BRAIN Biotech Stock
BRAIN Biotech Net Income→
BRAIN Biotech Stock
BRAIN Biotech P/E→
BRAIN Biotech Stock
BRAIN Biotech P/S→
BRAIN Biotech Stock
BRAIN Biotech EBIT→
BRAIN Biotech Stock
BRAIN Biotech Dividend→
BRAIN Biotech Stock
BRAIN Biotech Directors Dealings→
BRAIN Biotech Stock
BRAIN Biotech Stocks→
BRAIN Biotech Stock
BRAIN Biotech Market capitalization→
BRAIN Biotech Stock
BRAIN Biotech Debt→
BRAIN Biotech Stock
BRAIN Biotech Liabilities→
BRAIN Biotech Stock
BRAIN Biotech Equity→
BRAIN Biotech Stock
BRAIN Biotech AAQS→
BRAIN Biotech Stock
BRAIN Biotech Employees→
BRAIN Biotech Stock
BRAIN Biotech ROE→
BRAIN Biotech Stock
BRAIN Biotech ROA→
BRAIN Biotech Stock
BRAIN Biotech ROCE→
BRAIN Biotech Stock
BRAIN Biotech News→
BRAIN Biotech Stock
BRAIN Biotech Analyst Price Targets→

Commodities Stocks

BraskemBradesparBraskem SA Class ABpm MineralsBravada GoldBowler MetcalfBrazilian Critical MineralsBoundary Gold and Copper MiningBrazilian Rare EarthsBougainville CopperBRCK GroupBoubyan Petrochemical Company KSCPAll Stocks A–Z →